Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Type
1.5.2 Market Segmentation by End User
1.5.3 Market Segmentation by Region
1.6 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 P&S Intelligence Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Designation
2.2.2 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats
Chapter 3. Executive Summary
3.1 U.S.
3.2 Canada
3.3 Germany
3.4 France
3.5 U.K.
3.6 China
3.7 Japan
3.8 South Korea
3.9 India
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Definition of Market Segments
5.1 By Type
5.1.1 Drug Treatment
5.1.1.1 Alpha blockers
5.1.1.1.1 Alfuzosin
5.1.1.1.2 Doxazosin
5.1.1.1.3 Tamsulosin
5.1.1.1.4 Silodosin
5.1.1.1.5 Other alpha blockers
5.1.1.2 Alpha reductase inhibitors
5.1.1.2.1 Finasteride
5.1.1.2.2 Dutasteride
5.1.1.3 Others
5.1.2 Surgical Treatment
5.1.2.1 TURP
5.1.2.2 TUMT
5.1.2.3 TUNA
5.1.2.4 Laser therapy
5.1.2.5 Prostatic stenting
5.1.2.6 UroLift therapy
5.1.2.7 Rezûm therapy
5.1.2.8 Others
5.2 By End User
5.2.1 Home Healthcare
5.2.2 Hospitals & Clinics
Chapter 6. Industry Outlook
6.1 Market Dynamics
6.1.1 Trends
6.1.1.1 Technological advancements
6.1.1.2 Product approvals and launches
6.1.2 Drivers
6.1.2.1 Increasing geriatric male population
6.1.2.2 Rising prevalence of BPH
6.1.2.3 Surging awareness of BPH disorders
6.1.3 Impact Analysis of Drivers on Market Forecast
6.1.4 Restraints
6.1.4.1 Side effects associated with BPH medication
6.1.4.2 Unfavorable healthcare reforms
6.1.5 Impact Analysis of Restraints on Market Forecast
6.2 Impact of COVID 19
6.3 Porter’s Five Forces Analysis
6.3.1 Bargaining Power of Buyers
6.3.2 Bargaining Power of Suppliers
6.3.3 Intensity of Rivalry
6.3.4 Threat of New Entrants
6.3.5 Threat of Substitutes
Chapter 7. Policy and Regulatory Landscape
7.1 Regulations for BPH Treatment Devices
7.1.1 North America
7.1.2 Europe
7.1.3 APAC
7.1.4 LATAM
7.1.5 MEA
7.2 Regulatory Framework for Drug Approval
7.2.1 U.S.
7.2.2 Europe
7.2.2.1 Centralized procedure
7.2.2.2 Mutual recognition procedure
7.2.2.3 Decentralized procedure
7.2.2.4 Nationalized procedure
7.2.3 Japan
Chapter 8. Global Market Size and Forecast
8.1 Overview
8.2 Market Revenue, by Type
8.2.1 Global Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
8.2.1.1 Global benign prostatic hyperplasia alpha blockers market revenue, by type
8.2.1.2 Global benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
8.2.2 Global Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
8.3 Market Revenue, by End User
8.4 Market Revenue, by Region
Chapter 9. North America Market Size and Forecast
9.1 Overview
9.2 Market Revenue, by Type
9.2.1 North America Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
9.2.1.1 North America benign prostatic hyperplasia alpha blockers market revenue, by type
9.2.1.2 North America benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
9.2.2 North America Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
9.3 Market Revenue, by End User
9.4 Market Revenue, by Country
Chapter 10. U.S. Market Size and Forecast
10.1 Market Revenue, by Type
10.1.1 U.S. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
10.1.1.1 U.S. benign prostatic hyperplasia alpha blockers market revenue, by type
10.1.1.2 U.S. benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
10.1.2 U.S. Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
10.2 Market Revenue, by End User
Chapter 11. Canada Market Size and Forecast
11.1 Market Revenue, by Type
11.1.1 Canada Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
11.1.1.1 Canada benign prostatic hyperplasia alpha blockers market revenue, by type
11.1.1.2 Canada benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
11.1.2 Canada Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
11.2 Market Revenue, by End User
Chapter 12. Europe Market Size and Forecast
12.1 Overview
12.2 Market Revenue, by Type
12.2.1 Europe Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
12.2.1.1 Europe benign prostatic hyperplasia alpha blockers market revenue, by type
12.2.1.2 Europe benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
12.2.2 Europe Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
12.3 Market Revenue, by End User
12.4 Market Revenue, by Country
Chapter 13. Germany Market Size and Forecast
13.1 Market Revenue, by Type
13.1.1 Germany Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
13.1.1.1 Germany benign prostatic hyperplasia alpha blockers market revenue, by type
13.1.1.2 Germany benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
13.1.2 Germany Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
13.2 Market Revenue, by End User
Chapter 14. France Market Size and Forecast
14.1 Market Revenue, by Type
14.1.1 France Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
14.1.1.1 France benign prostatic hyperplasia alpha blockers market revenue, by type
14.1.1.2 France benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
14.1.2 France Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
14.2 Market Revenue, by End User
Chapter 15. U.K. Market Size and Forecast
15.1 Market Revenue, by Type
15.1.1 U.K. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
15.1.1.1 U.K. benign prostatic hyperplasia alpha blockers market revenue, by type
15.1.1.2 U.K. benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
15.1.2 U.K. Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
15.2 Market Revenue, by End User
Chapter 16. APAC Market Size and Forecast
16.1 Overview
16.2 Market Revenue, by Type
16.2.1 APAC Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
16.2.1.1 APAC benign prostatic hyperplasia alpha blockers market revenue, by type
16.2.1.2 APAC benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
16.2.2 APAC Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
16.3 Market Revenue, by End User
16.4 Market Revenue, by Country
Chapter 17. China Market Size and Forecast
17.1 Market Revenue, by Type
17.1.1 China Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
17.1.1.1 China benign prostatic hyperplasia alpha blockers market revenue, by type
17.1.1.2 China benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
17.1.2 China Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
17.2 Market Revenue, by End User
Chapter 18. Japan Market Size and Forecast
18.1 Market Revenue, by Type
18.1.1 Japan Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
18.1.1.1 Japan benign prostatic hyperplasia alpha blockers market revenue, by type
18.1.1.2 Japan benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
18.1.2 Japan Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
18.2 Market Revenue, by End User
Chapter 19. South Korea Market Size and Forecast
19.1 Market Revenue, by Type
19.1.1 South Korea Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
19.1.1.1 South Korea benign prostatic hyperplasia alpha blockers market revenue, by type
19.1.1.2 South Korea benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
19.1.2 South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
19.2 Market Revenue, by End User
Chapter 20. India Market Size and Forecast
20.1 Market Revenue, by Type
20.1.1 India Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
20.1.1.1 India benign prostatic hyperplasia alpha blockers market revenue, by type
20.1.1.2 India benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
20.1.2 India Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
20.2 Market Revenue, by End User
Chapter 21. LATAM Market Size and Forecast
21.1 Overview
21.2 Market Revenue, by Type
21.2.1 LATAM Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
21.2.1.1 LATAM benign prostatic hyperplasia alpha blockers market revenue, by type
21.2.1.2 LATAM benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
21.2.2 LATAM Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
21.3 Market Revenue, by End User
21.4 Market Revenue, by Country
Chapter 22. MEA Market Size and Forecast
22.1 Overview
22.2 Market Revenue, by Type
22.2.1 MEA Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
22.2.1.1 MEA benign prostatic hyperplasia alpha blockers market revenue, by type
22.2.1.2 MEA benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
22.2.2 MEA Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
22.3 Market Revenue, by End User
22.4 Market Revenue, by Country
Chapter 23. Competitive Landscape
23.1 List of Market Players and Their Offerings
23.2 Market Share Analysis of Key Players
23.2.1 Global BPH Drugs Market
23.2.2 Global BPH Surgical Treatment Market
23.3 Competitive Analysis of Key Players
23.4 Product Comparison of Key Players
23.5 Recent Strategic Developments of Key Players
23.5.1 Partnerships & Acquisitions
23.5.2 Geographical Expansions
23.5.3 Product Launches
23.5.4 Other Developments
Chapter 24. Company Profiles
24.1 Astellas Pharma Inc.
24.1.1 Business Overview
24.1.2 Product and Service Offerings
24.1.3 Key Financial Summary
24.2 Alembic Pharmaceuticals Limited
24.2.1 Business Overview
24.2.2 Product and Service Offerings
24.2.3 Key Financial Summary
24.3 Unilab Inc.
24.3.1 Business Overview
24.3.2 Product and Service Offerings
24.4 Pharex Health Corporation
24.4.1 Business Overview
24.4.2 Product and Service Offerings
24.5 Biolitec AG
24.5.1 Business Overview
24.5.2 Product and Service Offering
24.6 Urologix LLC
24.6.1 Business Overview
24.6.2 Product and Service Offerings
24.7 Advin Health Care
24.7.1 Business Overview
24.7.2 Product and Service Offerings
24.8 Asclepion Laser Technologies GmbH
24.8.1 Business Overview
24.8.2 Product and Service Offerings
24.9 Pnn Medical A/S
24.9.1 Business Overview
24.9.2 Product and Service Offerings
24.10 Quanta Systems
24.10.1 Business Overview
24.10.2 Product and Service Offerings
24.11 Abbott Laboratories
24.11.1 Business Overview
24.11.2 Product and Service Offerings
24.11.3 Key Financial Summary
24.12 Asahi Kasei Corporation
24.12.1 Business Overview
24.12.2 Product and Service Offerings
24.12.3 Key Financial Summary
24.13 Richard Wolf GmbH
24.13.1 Business Overview
24.13.2 Product and Service Offerings
24.14 Boston Scientific Corporation
24.14.1 Business Overview
24.14.2 Product and Service Offerings
24.14.3 Key Financial Summary
24.15 KARL STORZ SE & Co. KG
24.15.1 Business Overview
24.15.2 Product and Service Offerings
24.16 Teleflex Incorporated
24.16.1 Business Overview
24.16.2 Product and Service Offerings
24.16.3 Key Financial Summary
24.17 Olympus Corporation
24.17.1 Business Overview
24.17.2 Product and Service Offerings
24.17.3 Key Financial Summary
24.18 Pfizer Inc.
24.18.1 Business Overview
24.18.2 Product and Service Offerings
24.18.3 Key Financial Summary
24.19 Merck & Co. Inc.
24.19.1 Business Overview
24.19.2 Product and Service Offerings
Want a report tailored exactly to your business need?
Empowering Leaders Across the Globe
Leading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages